ArticleBMC microbiology2026
Microbial signatures with diagnostic potential in early gastric cancer: insights beyond H. pylori.
Article in BMC microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundThe involvement of the intratumoral microbiome in gastric cancer (GC) pathogenesis remains insufficiently characterized, particularly in early gastric cancer (EGC). Here, we explored the relationship between the microbial community and EGC, with a specific focus on Helicobacter pylori (Hp)-negative microbiota.
methodGastric mucosal microbiota from patients with EGC (n = 76) and healthy controls (HC, n = 39) were analyzed using 16 S rRNA V3-V4 amplicon sequencing. Linear discriminant analysis effect size (LEfSe) and random forest modeling were employed to identify microbial taxa that could serve as potential biomarkers distinguishing EGC from HC. In addition, the functional potential of the microbial communities was predicted using PICRUSt2, with annotation based on KEGG pathways.
resultsA total of 115 participants contributed 306 gastric mucosal samples. Significant microbial differences were observed across groups stratified by EGC and Hp status. In EGC-HP-Negative (EHN) group, Firmicutes and Actinobacteria decreased and Proteobacteria increased, accompanied by a reduced Firmicutes/Proteobacteria ratio. LEfSe analysis indicated that Prevotella and Enterococcus were markedly enriched, each presenting LDA scores above 4. In the random forest model, Prevotella was identified as the most influential genus for separating EHN from HC-HP-Negative (HHN), with the classifier achieving an AUC of 0.90. Microbial network complexity was highest in general EGC and lowest in EHN, whereas Hp infection enhanced network connectivity. Functional prediction indicated distinct microbial functional shifts among groups, characterized by enrichment of bile secretion and metabolic pathways in EHN and increased RNA-related pathways in EHP compared with HC.
conclusionGastric microbiota in EGC shows distinct alterations both with and without Hp. Prevotella may serve as a promising non-Hp microbial biomarker for early detection, while Hp further shapes microbial composition, network interactions, and pro-inflammatory pathways. These findings highlight the potential of targeting gastric microbiota for early diagnosis and therapeutic strategies in EGC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.